ISTH 2022 Congress
Hemophilia and Rare Bleeding Disorders » Hemophilia - Basic
Theme Navigation
- ISTH 2022 Congress
- Hemophilia and Rare Bleeding Disorders
- Hemophilia - Basic
- Hemophilia and Rare Bleeding Disorders
-
Abstract Number: OC 37.4
A humanized mouse model to assess the therapeutic potential of IdeS in hemophilia A with inhibitors
-
Abstract Number: PB0174
Activated Factor XI as Activator of Thrombin Generation to Increase Assay Sensitivity
-
Abstract Number: VPB0204
Association between platelet receptor genotypes and the bleeding tendency of hemophilia patients
-
Abstract Number: PB0181
Bleeding according to FVIII activity in 641 children with non-severe haemophilia – data from the PedNet study group
-
Abstract Number: OC 70.5
Bleeding in non-severe haemophilia A and B – data from the PedNet study group.
-
Abstract Number: PB0192
Bleeding Rates in Severe Non-inhibitor Haemophilia A Patients Across US, EU4&UK and Japan
-
Abstract Number: PB0199
Budget impact of increasing rVIII-SingleChain use in patients in Italy with moderate and severe hemophilia A
-
Abstract Number: VPB0206
Characterization of Anti-Emicizumab Antibodies Using Repository Samples Obtained in Clinical Studies of Emicizumab Conducted in Japan
-
Abstract Number: VPB0208
Coagulant potential of emicizumab in child hemophilia A patients
-
Abstract Number: PB0177
Detection of IgG4 anti-FVIII levels as complementary test to define the ITI outcome in patients with hemophilia A: results from the BrazIT Study
-
Abstract Number: OC 50.4
Differences in bleeding profiles and venous clot structures between emicizumab and factor VIII-treated mice
-
Abstract Number: PB0191
DNA extracellular traps as potential biomarker of chronic haemophilic synovitis and therapeutic perspective in patients treated with PRP
-
Abstract Number: PB0193
Dose optimization for prophylaxis using a pharmacokinetic model for factor IX products in severe hemophilia B
-
Abstract Number: OC 30.2
Efficacy of emicizumab prophylaxis in patients with severe hemophilia A in Germany: Real-life-data documented by eDiary smart medication
-
Abstract Number: PB0179
Establishment of a monolayer-based LSEC-like endothelial cell in vitro system from induced pluripotent stem cells
-
Abstract Number: PB0185
Exploring red blood cells as a novel tolerogenic approach for factor VIII inhibitors employing immuno-dominant FVIII derived peptides presented on MHC class II
-
Abstract Number: OC 07.4
Exploring the conformational landscape of Factor VIII B domain in order to generate an all atom full length structure of the coagulation Factor VIII protein
-
Abstract Number: VPB0207
Factor VIII K1813A has high affinity for activated factor IX and enhances global coagulation function
-
Abstract Number: PB0187
FIX binding to collagen IV generates thrombin via the extrinsic tenase
-
Abstract Number: OC 37.2
Follicular regulatory T cells promote anti-FVIII inhibitor development in hemophilia A mice